CORT
Corcept Therapeutics Incorporated · Healthcare
Insiders bought $3.3M of Corcept Therapeutics Incorporated in the last 12 months
1 insider bought on 1 day.
CORT over the last year
Largest buyers, last 12 months
CORT after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
185 insider filings since 2016, newest first
Daniel N Swisher Jr · Director
William Guyer · Chief Development Officer
William Guyer · Chief Development Officer
Gary Charles Robb · Chief Business Officer
William Guyer · Chief Development Officer
Gary Charles Robb · Chief Business Officer
William Guyer · Chief Development Officer
William Guyer · Chief Development Officer
Joseph Douglas Lyon · Insider
Gary Charles Robb · Chief Business Officer
Daniel N Swisher Jr · Director
William Guyer · Chief Development Officer
Joseph Douglas Lyon · Insider
Daniel N Swisher Jr · Director
William Guyer · Chief Development Officer
Gary Charles Robb · Chief Business Officer
Sean Maduck · Insider
Joseph Douglas Lyon · Insider
Joseph Douglas Lyon · Insider
Daniel N Swisher Jr · Director
Joseph Douglas Lyon · Insider
Daniel N Swisher Jr · Director
Sean Maduck · Insider
Sean Maduck · Insider
Daniel N Swisher Jr · Director
Joseph Douglas Lyon · Chief Accounting Officer
Sean Maduck · Insider
Daniel N Swisher Jr · Director
Daniel N Swisher Jr · Director
William Guyer · Chief Development Officer
Gary Charles Robb · Chief Business Officer
Daniel N Swisher Jr · Director
Joseph Douglas Lyon · Chief Accounting Officer
Sean Maduck · Insider
Joseph Douglas Lyon · Chief Accounting Officer
Sean Maduck · Insider
Daniel N Swisher Jr · Director
Sean Maduck · Insider
Sean Maduck · Insider
Joseph Douglas Lyon · Chief Accounting Officer
Joseph Douglas Lyon · Chief Accounting Officer
Daniel N Swisher Jr · Director
Sean Maduck · Insider
Sean Maduck · Insider
Gary Charles Robb · Chief Business Officer
Daniel N Swisher Jr · Director
Joseph Douglas Lyon · Chief Accounting Officer
Joseph Douglas Lyon · Chief Accounting Officer
David L Mahoney · Director
Hazel Hunt · Chief Scientific Officer
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.